On December 20, Glenorchy reported that Shanghai Medicilon Inc. (688202.SH) recently stated during a tour for institutional investors that the company is laying out multiple points in core overseas Industry areas such as the USA, Europe, and Asia-Pacific, strengthening laboratory capabilities and the Business team's construction. Currently, the company has more than ten members in its BD team in the USA and will continue to enhance the team's construction for the European market, increase communication between overseas BD and domestic research teams, establish a customer information intelligence system, manage major customer service well, and gradually build a market sales system that adapts to overseas market competition. In addition, the company will actively participate in overseas Industry conferences, increase the regular expansion frequency of the research team, and proactively expand overseas markets.
In the first three quarters of 2024, revenue from overseas customers accounted for approximately 36% of the main Business income, with overseas Orders increasing year-on-year. Currently, the company has invested approximately 2,000 square meters of research and development office space in Boston, USA, covering services in chemistry, biology, and animal experiments, which are now in operation and generating revenue. The Boston laboratory will cooperate and coordinate with domestic research and development laboratories, while sharing resources to achieve differentiated development, focusing on meeting the growing needs of overseas customers, continuously strengthening communication and cooperation with Global partners, and providing effective support for the Business expansion of clients in the USA and Europe, aiming to gradually increase the share of overseas Business to 40-50%, providing new ideas, new directions, and new momentum for the company's growth and development.